Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study-Reference-Cited by-同舟云学术

Orodispersible minitablets of enalapril for use in children with heart failure (LENA): Rationale and protocol for a multicentre pharmacokinetic bridging study and follow-up safety study

Published:2019-09 Issue: Volume:15 Page:100393
ISSN:2451-8654
Container-title:Contemporary Clinical Trials Communications
language:en
Short-container-title:Contemporary Clinical Trials Communications

Author:

Bajcetic Milica,de Wildt Saskia N.,Dalinghaus Michiel,Breitkreutz Jörg,Klingmann Ingrid,Lagler Florian B.,Keatley-Clarke Anne,Breur Johannes MPJ.,Male Christoph,Jovanovic Ida,Szatmári Andras,Ablonczy László,Burckhardt Bjoern B.,Cawello Willi,Kleine Karl,Obarcanin Emina,Spatenkova Lucie,Swoboda Vanessa,van der Meulen Marijke,Wagner Peter,Walsh Jennifer,Läer Stephanie

Funder

Paracelsus Medizinische Privatuniversität, Salzburg, Austria

“Labelling of Enalapril from Neonates up to Adolescents” (LENA)

EU’s Seventh Framework Programme (FP7/2007–2013)

Publisher

Elsevier BV

Subject

Pharmacology,General Medicine

Reference30 articles.

1. Plasma norepinephrine levels in infants and children with congestive heart failure;Ross;Am. J. Cardiol.,1987

2. Overview of the management of pediatric heart failure;Auslender;Prog. Pediatr. Cardiol.,2000

3. The International Society of Heart and Lung Transplantation Guidelines for the management of pediatric heart failure: executive summary;Kirk;J. Heart Lung Transplant.,2014